Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx-99, an Experimental Treatment for Respiratory Viral Infection, Including COVID-19
-Topline data anticipated by end of first quarter 2021- MENLO PARK, Calif.--(BUSINESS WIRE)--#SARSCoV2--Revelation Biosciences Inc.…